Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACE study of treat-to-target secukinumab in axial spondyloarthritis
2017-004037-93Phase 4Completed
- Sponsor
- Afdeling for Rygkirurgi, Led- og Bindevævssygdomme
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of secukinumab in axial spondyloarthritis (axSpA) and ankylosing spondylitis (AS) (2 arms), sponsored by Afdeling for Rygkirurgi, Led- og Bindevævssygdomme. Started Nov 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
axial spondyloarthritis (axSpA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2017-004037-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004037-93.